Prospective study to evaluate the effectiveness of Sofosbuvir/Ledipasvir without Ribavirin in patients with recurrent hepatitis C infection post liver transplant
Latest Information Update: 15 Feb 2017
Price :
$35 *
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics; Therapeutic Use
- 15 Feb 2017 New trial record